PubMed Health treatment related to Decubitus Ulcer: 62
As much pressure as possible should be taken off of the pressure ulcer . The most important thing is to stop sitting or lying on the wound . Special positioning aids, special soft mattresses, and regular repositioning and movement help to relieve the pressure. Sterile wound dressings are usually used to protect the wound and help it to heal. If necessary, the wound is also regularly cleaned and dead tissue removed. The most appropriate treatment will depend on the type and severity of the pressure ulcer .
Drugs for Decubitus Ulcer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 168)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
acetic acid |
Approved |
Phase 4 |
|
64-19-7 |
176 |
Synonyms:
Acetate
Acetic acid glacial
Acetic acid, glacial
Aceticum acidum
Acid glacial, acetic
Acid, acetic
Acid, glacial acetic
Acide acetique
acide acétique
ácido acético
AcOH
CH3CO2H
CH3-COOH
e 260
e260
e-260
Essigsaeure
Essigsäure
Ethanoat
|
Ethanoate
Ethanoic acid
Ethoate
Ethoic acid
Ethylate
Ethylic acid
Glacial acetate
Glacial acetic acid
Glacial, acetic acid
HOAc
INS no. 260
Kyselina octova
MeCO2h
MeCOOH
Methanecarboxylate
Methanecarboxylic acid
Vinegar
Vinegar acid
|
|
2 |
|
Rotigotine |
Approved |
Phase 4 |
|
99755-59-6, 92206-54-7 |
57537 |
Synonyms:
(6S)-6-(propyl(2-(2-thienyl)ethyl)amino)-5,6,7,8-tetrahydro-1-naphthalenol
2-(N-N-Propyl-N-2-thienylethylamino)-5-hydroxytetralin
N 0437, (-)-Isomer
N 0437, (+-)-Isomer
N 0437, (R)-Isomer
N 0437, Hydrochloride, (R)-isomer
|
N 0437, Hydrochloride, (S)-isomer
Neupro
Rotigotina
Rotigotine
Rotigotine CDS
|
|
3 |
|
Midazolam |
Approved, Illicit |
Phase 4 |
|
59467-70-8 |
4192 |
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
Dazolam
DB00683
Dea no. 2884
Dea No. 2884
DEA No. 2884
Dormicum
Dormicum (TN)
EINECS 261-774-5
|
Hydrochloride, midazolam
LS-77780
Maleate, midazolam
Midanium
midazolam
Midazolam
Midazolam (JAN/INN)
Midazolam [INN:BAN:JAN]
Midazolam base
Midazolam Base
Midazolam Hcl
Midazolam hydrochloride
Midazolam maleate
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
nchembio747-comp32
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
|
|
4 |
|
Nitric Oxide |
Approved |
Phase 4 |
|
10102-43-9 |
145068 |
Synonyms:
(.)NO
(no)(.)
(NO)(.)
[no]
[NO]
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous nitrate vasodilator
Endogenous Nitrate Vasodilator
Endothelium-derived nitric oxide
Endothelium-Derived Nitric Oxide
endothelium-derived relaxing factor
Endothelium-derived relaxing factor
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, Mononitrogen
Monoxide, nitrogen
Monoxide, Nitrogen
monoxido de nitrogeno
monoxido De nitrogeno
Monóxido de nitrógeno
monoxyde d'azote
Monoxyde d'azote
Nitrate vasodilator, endogenous
Nitrate Vasodilator, Endogenous
|
nitric oxide
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, endothelium derived
Nitric Oxide, Endothelium Derived
Nitric oxide, endothelium-derived
Nitric Oxide, Endothelium-Derived
NITRIC-OXIDE
nitrogen monooxide
Nitrogen monooxide
nitrogen monoxide
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
nitrosyl
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
no(.)
NO(.)
OHM 11771
Oxide, nitric
Oxide, Nitric
oxido de nitrogeno(II)
oxido De nitrogeno(II)
óxido de nitrógeno(II)
oxido nitrico
oxido Nitrico
óxido nítrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, endogenous nitrate
Vasodilator, Endogenous Nitrate
|
|
5 |
|
Sufentanil |
Approved, Investigational |
Phase 4 |
|
56030-54-7 |
41693 |
Synonyms:
56030-54-7
60561-17-3 (citrate)
AC1L26AJ
AC1Q5I7B
C08022
C22H30N2O2S
CHEBI:127638
CHEBI:9316
CHEMBL658
Chronogesic
CID41693
Citrate, sufentanil
Curasan brand OF sufentanil citrate
D05938
DB00708
Hameln brand OF sufentanil citrate
HSDB 6760
Janssen brand OF sufentanil citrate
L000580
LS-175693
MolPort-004-286-008
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide
N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide
Oprea1_120838
|
Oprea1_246787
PDSP1_001741
PDSP2_001724
R 30730
R-30730
Ratiopharm brand OF sufentanil citrate
Sufenta
sufentanil
Sufentanil
SUFENTANIL
Sufentanil (USAN/INN)
Sufentanil [USAN:BAN:INN]
Sufentanil citrate
Sufentanil Citrate
Sufentanil curasan
Sufentanil-hameln
Sufentanilo
Sufentanil-ratiopharm
Sufentanilum
Sufentanilum [INN-Latin]
Sufentanyl
Sulfentanil
Sulfentanil Citrate
Sulfentanyl
Taylor brand OF sufentanil citrate
UNII-AFE2YW0IIZ
|
|
6 |
|
Silicon |
Approved, Investigational |
Phase 4 |
|
7440-21-3 |
4082203 |
Synonyms:
|
Silicate
Silicic acid
silicio
|
|
7 |
|
Ketamine |
Approved, Vet_approved |
Phase 4 |
|
6740-88-1 |
3821 |
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
100477-72-3
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chloro-Phenyl)-2-methylamino-cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-Chlorophenyl)cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
Calipsol
Calypsol
Cetamina
Cetamina [INN-Spanish]
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
DivK1c_000217
|
dl-Ketamine
DL-ketamine
DL-Ketamine
EINECS 229-804-1
Esketamine
Green
IDI1_000217
Kalipsol
KBio1_000217
Ketaject
Ketalar
Ketalar base
Ketamina
ketamine
Ketamine
Kétamine
Ketamine (INN)
Ketamine [INN:BAN]
Ketamine base
Ketamine Base
Ketamine HCL
KETAMINE HCL
Ketamine hydrochloride
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketaset
Ketoject
Ketolar
l-Ketamine
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
|
|
8 |
|
St. John's Wort |
Approved, Investigational, Nutraceutical |
Phase 4 |
|
84082-80-4 |
|
Synonyms:
Common st johnswort flowering top
Common st. john's wort flowering top
Common st. john's wort herb
Common st. johnswort flowering top
Guanyejinsitao
Hyperici herba
Hypericum nachitschevanicum flowering top
Hypericum perforatum flowering top
Hypoxis hemerocallidea root extract
|
Klamath weed flowering top
Klamathweed flowering top
Saint johns wort
St john's wort
St Johns Wort
St. john’s wort
St. johns wort
St. johnswort flowering top
|
|
9 |
|
Retinol acetate |
|
Phase 4 |
|
127-47-9 |
10245972 |
Synonyms:
13-cis-Retinyl acetate
Acetateall-trans-retinol
Acetic acid, retinyl ester
all-trans-Retinol acetate
all-trans-Retinyl acetate
all-trans-Retinylacetate
all-trans-Vitamin a acetate
Crystalets
Dagravit a forte
Davitan a 650
Dif vitamin a masivo
Myvak
Myvax
O(15)-Acetylretinol
O~15~-acetylretinol
O~15~-acetyl-retinol
RetiNit
|
Retinol acetate (JP15)
RETINOL acetATE (see retinoidprojects 1 and 3)
Retinol acetate, (9,13-cis)-isomer
Retinol, acetate
Retinol, acetate, all-trans- (8ci)
Retinol, acetate, labeled with tritium
Retinyl acetate
trans-Retinyl acetate
trans-Vitamin a acetate
Vitamin a acetate
Vitamin a acetate (tritiated)
Vitamin a alcohol acetate
Vitamin a dispersa
Vitamin a ester
Vitamin a, acetate
Vitamin a1 acetate
Vitamin-a-saar
|
|
10 |
|
Olive |
|
Phase 4 |
|
|
|
11 |
|
Dopamine agonists |
|
Phase 4 |
|
|
|
12 |
|
Trace Elements |
|
Phase 4 |
|
|
|
13 |
|
Micronutrients |
|
Phase 4 |
|
|
|
14 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
15 |
|
Narcotics |
|
Phase 4 |
|
|
|
16 |
|
Disinfectants |
|
Phase 4 |
|
|
|
17 |
|
Nutrients |
|
Phase 4 |
|
|
|
18 |
|
Anesthetics |
|
Phase 4 |
|
|
|
19 |
|
Analgesics |
|
Phase 4 |
|
|
|
20 |
|
Hormones |
|
Phase 4 |
|
|
|
21 |
|
Excitatory Amino Acid Antagonists |
|
Phase 4 |
|
|
|
22 |
|
Anesthetics, Dissociative |
|
Phase 4 |
|
|
|
23 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
24 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
25 |
|
Anesthetics, Intravenous |
|
Phase 4 |
|
|
|
26 |
|
Polihexanide |
Approved, Investigational |
Phase 3 |
|
28757-47-3 |
|
Synonyms:
Polyhexamethylene biguanide
|
|
|
27 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
437-38-7 |
3345 |
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
28 |
|
Curcumin |
Approved, Experimental, Investigational |
Phase 3 |
|
458-37-7 |
969516 |
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. 75300
C.I. natural yellow 3
CI natural yellow 3
Cucurmin
Curcuma
Curcumin I
Diferaloylmethane
Diferuloylmethane
e 100
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
|
Hydrastis
Kacha haldi
Merita earth
Natural yellow 3
Orange root
Safran d'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yellow, turmeric
yo-Kin
|
|
29 |
|
Lopinavir |
Approved |
Phase 2, Phase 3 |
|
192725-17-0 |
92727 |
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
378, ABT
A 157378
A 157378.0
A-157378.0
A-157378-0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
ABT-378a-157378-0a-157378.0
AC1L3OPJ
AIDS032937
Aluviran
|
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Kaletra
Koletra
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
LPV
LS-173766
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
|
|
30 |
|
Hydroxychloroquine |
Approved |
Phase 2, Phase 3 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
747-36-4 (sulfate (1:1) salt)
7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
AC1L1GEW
Axemal
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
Dolquine
EINECS 204-249-8
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
|
Hidroxicloroquina
Hidroxicloroquina [inn-spanish]
Hidroxicloroquina [INN-Spanish]
HMS502P04
Hydroxychlorochin
Hydroxychloroguine
hydroxychloroquine
Hydroxychloroquine
Hydroxychloroquine (INN)
Hydroxychloroquine [INN:BAN]
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [dcit]
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Plaquenil
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
Spectrum2_001238
Spectrum5_001697
ST072188
UNII-4QWG6N8QKH
WIN 1258
|
|
31 |
|
Ritonavir |
Approved, Investigational |
Phase 2, Phase 3 |
|
155213-67-5 |
392622 |
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
32 |
|
Azithromycin |
Approved |
Phase 2, Phase 3 |
|
83905-01-5 |
447043 55185 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside
121470-24-4
1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-,(2R-(2R*,3S*
75199_FLUKA
83905-01-5
9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A
AC-16014
AC1L9KEG
Aritromicina
Azadose
Azasite
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
azithromycin
Azithromycin
Azithromycin & Tumor Necrosis Factor
Azithromycin (AIDS Initiative)
Azithromycin (anhydrous)
Azithromycin dihydrate
Azithromycin monohydrate
Azithromycin Monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromax
Azitromicina
Azitromin
Azythromycin
Bayer brand OF azithromycin dihydrate
BIDD:GT0792
Bio-0676
BRN 5387583
BSPBio_002285
C38H72N2O12
CCRIS 1961
CHEBI:2955
CHEMBL529
CID447043
CP62,993
CP-62993
CPD000471864
DCH3
Dihydrate, azithromycin
DivK1c_000233
DRG-0104
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
HMS1922G12
|
HMS2094M11
HMS500L15
HSDB 7205
IDI1_000233
KBio1_000233
KBio2_000787
KBio2_003355
KBio2_005923
KBio3_001505
KBioGR_000731
KBioSS_000787
Lesvi brand OF azithromycin dihydrate
LS-1834
Mack brand OF azithromycin dihydrate
Misultina
MLS001055353
MLS001066331
MLS001201763
MLS001304005
MLS001332499
MLS001332500
MolPort-002-507-426
Monohydrate, azithromycin
NCGC00090753-01
NCGC00090753-02
NINDS_000233
NSC643732
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
SAM002589961
SMR000471864
SPBio_001544
Spectrum_000307
SPECTRUM1503679
Spectrum2_001582
Spectrum3_000653
Spectrum4_000186
Spectrum5_001867
Sumamed
Toraseptol
Tromix
Ultreon
UNII-JTE4MNN1MD
Vinzam
Vita brand OF azithromycin dihydrate
XZ-450
Zentavion
ZIT
Zithromac
Zithromax
Zithromax IV
Zithromycin
Zitromax
Zitromax Avium 600
Zmas
Zmax
Z-Pak
|
|
33 |
|
Oxandrolone |
Approved, Investigational |
Phase 3 |
|
53-39-4 |
5878 |
Synonyms:
(1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one
(4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one
17beta-Hydroxy-17alpha-methyl-2-oxa-5alpha-androstan-3-one
17beta-Hydroxy-17-methyl-2-oxa-5alpha-androstan-3-one
17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one
17-beta-hydroxy-17-methyl-2-oxa-androstan-3-one (9CI)
2-Oxa-5alpha-androstan-3-one, 17beta-hydroxy-17-methyl- (8CI)
2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5-alpha,17-beta)- (9CI)
53-39-4
8075 C. B
8075 C. B.
8075 C.B
8075 C.B.
8075 CB
AC-14975
AC1L1LBY
Ambap53-39-4
Anavar
C07346
C19H30O3
CHEBI:7820
CHEMBL1200436
CID5878
D00462
DB00621
Dodecahydro-3-hydroxy-6-(hydroxy-methyl)-3,3a,6-trimethyl-1H-benz(e)indene-7-acetic acid delta-lactone
EINECS 200-172-9
HSDB 3373
|
Lonavar
LS-98540
MolPort-003-986-935
NSC 67068
Ossandrolone
Ossandrolone [DCIT]
Oxandrin
Oxandrin (TN)
Oxandrin, Anavar, Oxandrolone
Oxandrolon
Oxandrolona
Oxandrolona [INN-Spanish]
Oxandrolone
OXANDROLONE
Oxandrolone (JAN/USP/INN)
Oxandrolone [USAN:INN:BAN:JAN]
Oxandrolonum
Oxandrolonum [INN-Latin]
Protivar
Provitar
S1753_Selleck
SC 11585
SC-11585
TL8003512
UNII-7H6TM3CT4L
Vasorome
ZINC03813047
|
|
34 |
|
Tamsulosin |
Approved, Investigational |
Phase 3 |
|
106133-20-4 |
129211 |
Synonyms:
(−)-tamsulosin
(R)-(−)-tamsulosin
(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulphonamide
106133-20-4
5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide
5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulphonamide
5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
AC1L2V76
BIDD:GT0261
C07124
C20H28N2O5S
CHEBI:9398
CHEMBL836
CID129211
D08560
DB00706
Flomax
Flomax (TN)
Flowmax
|
FT-0082894
Harnal
HMS2090P15
LS-31578
MolPort-003-850-388
NCGC00167442-01
Omnic
Pradif
STK626950
Tamsolusin
Tamsulon
Tamsulon (TN)
tamsulosin
Tamsulosin
TAMSULOSIN
Tamsulosin (INN)
Tamsulosin [INN:BAN]
Tamsulosin hydrochloride
Tamsulosina
Tamsulosina [INN-Spanish]
Tamsulosine
Tamsulosine [INN-French]
Tamsulosinum
Tamsulosinum [INN-Latin]
UNII-G3P28OML5I
YM-617
|
|
35 |
|
Anti-Anxiety Agents |
|
Phase 3 |
|
|
|
36 |
|
GABA Modulators |
|
Phase 3 |
|
|
|
37 |
|
Antioxidants |
|
Phase 3 |
|
|
|
38 |
|
Omega 3 Fatty Acid |
|
Phase 3 |
|
|
|
39 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
40 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
41 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 3 |
|
|
|
42 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3 |
|
|
|
43 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3 |
|
|
|
44 |
|
Antirheumatic Agents |
|
Phase 2, Phase 3 |
|
|
|
45 |
|
Antiviral Agents |
|
Phase 2, Phase 3 |
|
|
|
46 |
|
protease inhibitors |
|
Phase 2, Phase 3 |
|
|
|
Synonyms:
|
47 |
|
HIV Protease Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
48 |
|
Antiparasitic Agents |
|
Phase 2, Phase 3 |
|
|
|
49 |
|
Antiprotozoal Agents |
|
Phase 2, Phase 3 |
|
|
|
50 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 386)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A 12-week, Single Site, Randomized Controlled Trial to Compare the Efficacy of Quantum NPWT With and Without Simultaneous Irrigation Versus Standard of Care on Reduction of the Volume of Stage III/IV Pressure Ulcers. |
Unknown status |
NCT01734109 |
Phase 4 |
|
2 |
Olive Oil's Cream Effectiveness in Prevention of Pressure Ulcers in Immobilized Patients in Primary Care.A Cluster Randomized Clinical Trial. |
Unknown status |
NCT01595347 |
Phase 4 |
Hyper-oxigenated fatty acid |
3 |
Post-Market Clinical Evaluation of the Spiracur SNaP Wound Care System |
Unknown status |
NCT01113658 |
Phase 4 |
|
4 |
Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury |
Unknown status |
NCT00201968 |
Phase 4 |
|
5 |
Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors |
Unknown status |
NCT03098368 |
Phase 4 |
Rotigotine;Placebo |
6 |
Negative Pressure Wound Therapy With the Engenexâ„¢-Pump and Bio-Domeâ„¢ Dressing, an Evaluation |
Unknown status |
NCT01107821 |
Phase 4 |
|
7 |
Evaluation of Wound Management for Sacral Pressure Ulcers With Necrotic Tissue |
Completed |
NCT02224638 |
Phase 4 |
|
8 |
A Six Month Randomized Open-Label Trial of Pressure Ulcer Healing With Microcyn® Skin and Wound Care With Preservatives Versus Sterile Saline in Adult Spinal Cord Injury Subjects |
Completed |
NCT02001558 |
Phase 4 |
Microcyn |
9 |
A Multi-centre, Post CE-mark, Open Study to Evaluate the Performance of Thin Self-adherent Dressing Coated With a Soft Silicone Layer on Subjects With High Risk of Category 2 or Above Pressure Ulceration |
Completed |
NCT01438541 |
Phase 4 |
|
10 |
Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation. Randomized Clinical Trial |
Completed |
NCT02526862 |
Phase 4 |
|
11 |
A Double-blind, Comparative, Superiority, Multi-centre Investigation Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers |
Completed |
NCT01036438 |
Phase 4 |
|
12 |
Determination of the 90% Effective Dose of a Sufentanil Bolus in Analgesia During Lateral Decubitus of Mechanically Ventilated Patients. |
Completed |
NCT01356732 |
Phase 4 |
Sufentanil |
13 |
Different Radiation Exposures to Patient and Endoscopists Between Performing ERCP in Patients Lying Prone and Left Lateral Decubitus |
Completed |
NCT01599351 |
Phase 4 |
|
14 |
A Prospective, Randomized, Controlled Clinical Investigation, Comparing Trauma to Peri-Wound Skin and Pain When Using Two Different Wound Dressings |
Completed |
NCT02904200 |
Phase 4 |
|
15 |
A Prospective, Comparative, Single-centre Clinical Evaluation to Investigate the Skin-to-skin Time of the First Surgical Debridement of Lower Extremity Ulcers With VERSAJETâ„¢ Hydrosurgery System and Conventional Debridement Techniques. |
Completed |
NCT00521027 |
Phase 4 |
|
16 |
Evaluation of Provase in the Post Burn Rehabilitation Population for Itch Control and Moisturization Properties |
Completed |
NCT00782054 |
Phase 4 |
|
17 |
Effect of Prolonged Decubitus on Bronchial Inflammation in COPD Patients Evaluated by Expired NO Concentration Assessment |
Completed |
NCT01555593 |
Phase 4 |
|
18 |
Randomized Controlled Clinical Trial of 2% Chlorhexidine Gluconate-Impregnated Bath Cloths to Prevent MRSA Colonization on Complex Continuing Care Units of Baycrest Hospital |
Completed |
NCT01717690 |
Phase 4 |
CHG antiseptic body cleanser |
19 |
A Monocentric, Comparative and Randomized Study on Pressure Ulcers Prevention With Mepilex® Border Sacrum Dressing in Scheduled Cardiovascular Surgery |
Recruiting |
NCT03823963 |
Phase 4 |
|
20 |
Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst |
Recruiting |
NCT02485860 |
Phase 4 |
|
21 |
A Randomized Controlled Trial of Enzymatic Debridement of Pressure Ulcers With Clostridial Collagenase Ointment (SANTYL®) or Hydrogel (SoloSite®) |
Terminated |
NCT02718625 |
Phase 4 |
|
22 |
A 12-week, Prospective, Open-label, Randomized, Controlled Clinical Trial Comparing Negative Pressure Wound Therapy (NPWT) to Standard Wound Care for the Treatment of Chronic Pressure Wounds of the Pelvic Region |
Terminated |
NCT00691821 |
Phase 4 |
|
23 |
Honey Dressings for Local Wound Care of Split Thickness Skin Graft and Free Tissue Transfer Donor Sites: A Prospective, Randomized, Controlled Trial. |
Terminated |
NCT02259491 |
Phase 4 |
|
24 |
The Effect and Tolerance of a Ketamine Subcutaneous Bolus, During Painful Care of Refractory Bed Sores, Ulcers and Vascular Wounds in a Palliative Care Unit |
Terminated |
NCT02587130 |
Phase 4 |
Ketamine |
25 |
A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers |
Withdrawn |
NCT02248077 |
Phase 4 |
|
26 |
Clinical Outcomes for Chronic Ulcers Treated With Clostridial Collagenase (SANTYL®) Versus Standard Care Within the Continuum of Care of an Accountable Care Organization (ACO) |
Withdrawn |
NCT02716519 |
Phase 4 |
|
27 |
Leptospermum Scoparium Honey and Wound Care for Pressure Ulcers |
Withdrawn |
NCT02689310 |
Phase 4 |
|
28 |
PEMF Effects on Pain After Abdominal Body Contouring |
Withdrawn |
NCT01762423 |
Phase 4 |
|
29 |
A Comparison of OASIS Wound Matrix With Approved Dressings for Split Thickness Skin Graft Donor Sites |
Withdrawn |
NCT02994589 |
Phase 4 |
|
30 |
Stem Cells In Wound Healing With Collagen Matrix as a Carrier |
Withdrawn |
NCT02314416 |
Phase 4 |
|
31 |
Monochromatic Phototherapy on Diabetic Foot Ulcers. A Twenty Weeks Prospective, Randomised, Double Blind, Multi-centre, Placebo Controlled Study |
Unknown status |
NCT00859599 |
Phase 3 |
|
32 |
Ketamine's Efficiency in the Treatment of Chronic Pain With an Added Inflammatory Component Exploring the Kynurenin Pathway. A Randomized, Double Blind, Placebo-controlled Trial |
Unknown status |
NCT03513822 |
Phase 3 |
Ketamine 10 MG/ML;Placebos;Midazolam 1 MG/ML |
33 |
The Fluid Therapy Strategy of the Patients With Acute Ischemic Stroke and a Bun/Cr Ratio Less Than 15. |
Unknown status |
NCT02668848 |
Phase 2, Phase 3 |
|
34 |
Interdisciplinary Pressure Management & Mobility Program as an Alternative to Bed Rest: A Pilot Study |
Completed |
NCT00796042 |
Phase 3 |
|
35 |
Interdisciplinary Mobility Approach To Reduction Of Facility-Acquired Pressure Ulcers |
Completed |
NCT01008254 |
Phase 2, Phase 3 |
|
36 |
Lifestyle Redesign for Pressure Ulcer Prevention in Spinal Cord Injury |
Completed |
NCT01999816 |
Phase 3 |
|
37 |
Preventing Pressure Ulcers: A Multi-site RCT in Nursing Facilities |
Completed |
NCT00665535 |
Phase 3 |
|
38 |
Pressure Ulcer Multi-disciplinary Teams Via Telemedicine (PUMTT): A Cluster Pragmatic Randomised Controlled Trial in Long Term Care |
Completed |
NCT01232764 |
Phase 3 |
|
39 |
Comparison of Two Turning Regimens (2 Versus Every 4 Hours) in the Prevention of Pressure Ulcers in Patients on Mechanical Ventilation That Use Alternating-pressure Air Mattresses. |
Completed |
NCT00847665 |
Phase 3 |
|
40 |
Maggot Therapy for Wound Debridement: a Randomized Multicentric Double-blind Trial |
Completed |
NCT01211236 |
Phase 3 |
|
41 |
Efficacy of Prontosan Solution on Chronic Ulcers |
Completed |
NCT01333670 |
Phase 3 |
Isotonic solution (saline or lactated ringer) |
42 |
Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly With or Without Background Treatment. |
Completed |
NCT02298582 |
Phase 2, Phase 3 |
intranasal fentanyl |
43 |
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing |
Completed |
NCT01214811 |
Phase 3 |
|
44 |
Neural Consequences of Chronic Inflammation in Individuals With Spinal Cord Injury and the Influence of an Anti-inflammatory Diet |
Completed |
NCT02099890 |
Phase 3 |
|
45 |
Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide: Randomized Clinical Trial |
Completed |
NCT02394821 |
Phase 3 |
Polihexanide 2%;Metronidazole 0.8% |
46 |
Erigo®Pro Coma Outcome Study - Study on the Effectiveness of a Robotic Tilt Table Device for Recovery of Consciousness |
Completed |
NCT02639481 |
Phase 3 |
|
47 |
A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Pressure Ulcers |
Recruiting |
NCT02312570 |
Phase 2, Phase 3 |
|
48 |
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial |
Not yet recruiting |
NCT04359095 |
Phase 2, Phase 3 |
Hydroxychloroquine;Lopinavir / Ritonavir Pill;Azithromycin |
49 |
Impact of Skin Dressings Compared With Cream for Skin Lubrication in the Prevention of Pressure Ulcers in Patients at High or Very High Risk: A Multicenter Randomized Trial |
Terminated |
NCT02565745 |
Phase 3 |
|
50 |
CSP #535 - Anabolic Steroid Therapy on Pressure Ulcer Healing in Persons With Spinal Cord Injury |
Terminated |
NCT00101361 |
Phase 3 |
Oxandrolone;Placebo |
Cochrane evidence based reviews: pressure ulcer
|